Atherosclerosis (Coronary Artery Disease/hardening of the arteries) Research Atherosclerosis refers to fatty deposit buildups in the arteries that carry oxygen and nutrient-rich blood to organs of the body. As these deposits occur, they can narrow the artery restricting or eventually stopping blood flow. This can lead to pain in the chest called angina, heart attack, stroke or other complications. OSU Medical Center research is actively involved in discovering better ways to prevent, diagnose and treat atherosclerosis. For information about OSU Medical Center heart research, call (614) 292-1616 between 8:30 a.m. and 4:30 p.m. weekdays.
Research Topic: Alternative/Complimentary Treatment for Coronary Heart Disease (CHD) Trial Name: Trial To Assess Chelation Therapy (TACT) Trial Description: TACT is a randomized, double-blind, placebo-controlled trial testing the effectiveness of c helation therapy in reducing the incidence of cardiovascular events (myocardial infarction, stroke) in people diagnosed with coronary heart disease (CHD). Specifically, chelation therapy is an alternative/complimentary medicine treatment that involves the intravenous administration of the drug EDTA (disodium ethylenediaminetetraacetic acid) combined with high-dose antioxidant vitamin and mineral supplements. Participants are randomized to receive either the standard chelation therapy solution as recommended by the American College for Advancement in Medicine or a placebo solution. All participants are followed for an average of 2.5 years. Trial Eligibility: Women (post-menopausal only) and men at least 50 years of age Trial Sponsor: (OSU Principal Investigator) National Center of Complementary Medicine; National Heart, Lung, and Blood Institute; and National Institutes of Health (Raymond Magorien, MD) Contact For Additional Trial Information: Trial Coordinator: Ovidiu Adam, MD, MS
Research Topic: Blood Thinning Medications for Acute Coronary Syndromes Trial Name: A Randomized Comparison of Angiomax (bivalirudin) Versus Heparin (unfractionated heparin or enoxaparin) in Patients Undergoing Early Invasive Management for Acute Coronary Syndromes without ST-Segment Elevation (ACUITY) Trial Description: ACUITY is a randomized, open-label, 3-arm, multi-center, Phase III research study comparing Angiomax versus Heparin in improving cardiovascular outcomes (death, myocardial infarction, bleeding) for people hospitalized with an acute coronary syndrome. Participants are randomized to receive one of three drug treatments during their hospitalization: Heparin with GPIIb/IIIa inhibitor therapy, Angiomax with GPIIb/IIIa inhibitor therapy, or Angiomax alone. Trial Eligibility: Men and non-pregnant women at least 18 years of age Trial Sponsor: (OSU Principal Investigator) Contact For Additional Trial Information WIRB Approval #1855659.0
Research Topic: Type II Diabetes and Coronary Heart Disease (CHD) Trial Name: Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation (PERISCOPE) Alternate Trial Name: A Double-Bind, Randomized, Comparator-Controlled Study in Subjects with Type II Diabetes Mellitus Comparing the Effects of Pioglitazone HCL versus Glimepiride on the Rate of Progression of Coronary Atherosclerotic Disease as Measured by Intravascular Ultrasound Trial Description: PERISCOPE is a trial comparing the effect of two diabetes medications on a change in atheroma (fatty plaque) in the arteries of the heart. Changes in the arteries are assessed using intravascular ultrasound (IVUS) imaging. Participants are randomized to receive either Pioglitazone HCL (Actos) or Glimepiride over a period of 18 months for treatment of their diabetes mellitus (Type II diabetes). Trial Eligibility: Contact For Additional Trial Information |
© The Ohio State University Medical Center.
410 W. 10th Avenue, Columbus, Ohio 43210
1-800-293-5123
The content of this Web site is for informational purposes only. It does not replace the advice of a physician. All material is the property of Ohio State University Medical Center. All rights reserved. Please see our disclaimer for more detail.